University Medical Centre Schleswig-Holstein
University Medical Centre Schleswig-Holstein is recorded as a service provider in 2 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 2 of 2 trials · Latest update first
A phase 3 multicentre, randomized, prospective, open-label trial of Ibrutinib monotherapy versus fixed-duration Venetoclax plus Obinutuzumab versus fixed-duration Venetoclax plus Ibrutinib in patients with previously untreated chronic lymphocytic leukaemia (CLL) - CLL17
Sponsor University Of Cologne
- Start (EU)
- Latest update
- Estimated end
Randomized phase II trial for patients with newly diagnosed low-risk multiple myeloma to evaluate the benefit of 6 cycles of isatuximab with lenalidomide/bortezomib/dexamethasone (I-VRD) followed by maintenance therapy with lenalidomide and isatuximab randomized in comparison with therapy consisting of 3 cycles of I-VRD followed by one cycle of high-dose therapy and maintenance therapy with lenalidomide and isatuximab
Sponsor University Medical Centre Schleswig-Holstein
- Start (EU)
- Latest update
- Estimated end
- Not reported
Questions about this trial experience
What services are recorded for University Medical Centre Schleswig-Holstein?
The 2026-10-09 snapshot links University Medical Centre Schleswig-Holstein to 2 distinct CTIS trials. Recorded services include Laboratory services, Data management. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for University Medical Centre Schleswig-Holstein?
The most frequently recorded therapeutic areas are Haematological Malignancies. Recorded phases include Phase 3. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to University Medical Centre Schleswig-Holstein conducted?
The linked trials record locations in 11 countries, including Germany, Austria, Belgium, Denmark, Spain. These are trial locations, not confirmed office locations or countries where University Medical Centre Schleswig-Holstein delivered services.
What can this page tell me about University Medical Centre Schleswig-Holstein's trial experience?
Browse 2 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. No trial-level operational findings are recorded in this snapshot. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under University Medical Centre Schleswig-Holstein. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- University Medical Centre Schleswig-Holstein